The estimated Net Worth of Vincent Milano is at least $1.53 Million dollars as of 1 June 2024. Mr. Milano owns over 4,660 units of Idera Pharmaceuticals stock worth over $5,385 and over the last 15 years he sold IDRA stock worth over $190,116. In addition, he makes $1,337,220 as President, Chief Executive Officer und Director at Idera Pharmaceuticals.
Sign up
Mr. Milano IDRA stock SEC Form 4 insiders trading
Vincent has made over 14 trades of the Idera Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 4,660 units of IDRA stock worth $2,004 on 1 June 2024.
The largest trade he's ever made was buying 200,000 units of Idera Pharmaceuticals stock on 12 December 2014 worth over $800,000. On average, Vincent trades about 6,330 units every 57 days since 2010. As of 1 June 2024 he still owns at least 12,523 units of Idera Pharmaceuticals stock.
You can see the complete history of Mr. Milano stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Vincent Milano biography
Vincent J. Milano CPA serves as President, Chief Executive Officer, Director of the Company. Prior to joining us, Mr. Milano served as Chairman, President and Chief Executive Officer of ViroPharma Inc., which was acquired by Shire Plc in January 2014, from March 2008 to January 2014, as its Vice President, Chief Financial Officer and Chief Operating Officer from January 2006 to March 2008 and as its Vice President, Chief Financial Officer and Treasurer from April 1996 to December 2005. Mr. Milano also served on the board of directors of ViroPharma from March 2008 to January 2014. Prior to joining ViroPharma, Mr. Milano served in increasingly senior roles, most recently senior manager, at KPMG LLP, an independent registered public accounting firm, from July 1985 to March 1996. Mr. Milano currently serves on the board of directors of Spark Therapeutics, Inc. and Vanda Pharmaceuticals Inc., each a publicly traded company, and VenatoRx Pharmaceuticals, Inc. Mr. Milano holds a Bachelor of Science degree in Accounting from Rider College. He also has corporate governance experience through service on other public company boards.
What is the salary of Vincent Milano?
As the President, Chief Executive Officer und Director of Idera Pharmaceuticals, the total compensation of Vincent Milano at Idera Pharmaceuticals is $1,337,220. There are no executives at Idera Pharmaceuticals getting paid more.
How old is Vincent Milano?
Vincent Milano is 56, he's been the President, Chief Executive Officer und Director of Idera Pharmaceuticals since 2014. There are 12 older and 4 younger executives at Idera Pharmaceuticals. The oldest executive at Idera Pharmaceuticals, Inc. is Dr. Sudhir Agrawal D.Phil., DPHIL, F.R.S.C., 67, who is the Scientific Advisor.
What's Vincent Milano's mailing address?
Vincent's mailing address filed with the SEC is 4505 EMPEROR BLVD., SUITE 200, DURHAM, NC, 27703.
Insiders trading at Idera Pharmaceuticals
Over the last 17 years, insiders at Idera Pharmaceuticals have traded over $20,746,904 worth of Idera Pharmaceuticals stock and bought 38,459,430 units worth $53,771,070 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp Baker Bro... und Invest Corp Pillar Pharmace.... On average, Idera Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $309,429. The most recent stock trade was executed by John J. Kirby on 17 December 2021, trading 10,000 units of IDRA stock currently worth $6,200.
What does Idera Pharmaceuticals do?
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
What does Idera Pharmaceuticals's logo look like?
Complete history of Mr. Milano stock trades at Aclaris Therapeutics Inc, Biocryst Pharmaceuticals, Idera Pharmaceuticals und Vanda Pharmaceuticals Inc
Idera Pharmaceuticals executives and stock owners
Idera Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Vincent Milano,
President, Chief Executive Officer, Director -
Robert Fletcher,
Senior Vice President - Business Development and Strategic Planning -
Bryant Lim,
Senior Vice President, General Counsel, Corporate Secretary -
John Kirby,
Chief Financial Officer, Senior Vice President -
Bryant David Lim,
Sr. VP, Gen. Counsel & Corp. Sec. -
John J. Kirby,
Sr. VP & CFO -
Vincent J. Milano,
Pres, CEO & Director -
james Geraghty,
Independent Chairman of the Board -
Carol Schafer,
Independent Director -
Maxine Gowen,
Independent Director -
Mark Goldberg,
Independent Director -
Michael Dougherty,
Independent Director -
Cristina Csimma,
Independent Director -
Elizabeth Tarka,
Senior Vice President, Chief Medical Officer -
Louis J. Arcudi III, M.B.A., MBA,
Adviser -
Dr. Sudhir Agrawal D.Phil., DPHIL, F.R.S.C.,
Scientific Advisor -
Dr. Sudhir Agrawal,
Scientific Advisor -
Dr. Joanna C. Horobin Ch.B, M.B.,
Advisor -
Dr. Shah Rahimian M.D., Ph.D.,
Medical Director & Global Clinical Lead for Oncology -
Elizabeth Eberhardt,
Sr. VP of Product Leadership -
Jill Conwell,
Sr. VP of Investor Relations & Corp. Communications -
Daniel B. Soland,
Sr. VP & COO -
Bros. Advisors Lp667, L.P.B...,
-
William S Reardon,
Director -
Invest Corp Pillar Pharmace...,
-
Iii Louis J Arcudi,
Chief Financial Officer -
Julianbaker Bros. Advisors ...,
-
Invest Corp Pillar Pharmace...,
-
Bros. Advisors Lp Baker Bro...,
-
Invest Corp Pillar Pharmace...,
-
Mark J Casey,
Senior VP and General Counsel -
Julian Baker Bros. Advisors...,
-
Youssef El Zein,
Director -
Bros. Advisors Lp Baker Bro...,
-
Alice Bexon,
V.P. Clinical Development -
Alison Taunton Rigby,
Director -
Sudhir Agrawal,
CEO & CSO -
Invest Corp Pillar Pharmace...,
-
Bros. Advisors Lp14159, L.P...,
-
Invest Corp Pillar Pharmace...,
-
Invest Corp Pillar Pharmace...,
-
Jonathan Michael Yingling,
Chief Scientific Officer -
Invest Corp Pillar Pharmace...,
-
Invest Corp Pillar Pharmace...,
-
Howard H Pien,
Director -
Invest Corp Pillar,
10% owner -
Paul C Zamecnik,
-
Joanna Horobin,
SVP and Chief Medical Officer -
Eve Elizabeth Slater,
Director -
Malcolm Mac Coss,
Director -
Timothy M Sullivan,
VP Development Programs -
Umari Abdul Wahab,
Director -
Louis Md Brenner,
Chief Medical Officer -
Robert D. Arbeit,
VP Clinical Development -
Robert W Karr,
Director -
Pharmaceuticals I Lpzein Yo...,
-
John Peter Iii Wolf,
General Counsel -
Invest Corp Pillar Pharmace...,
-
C Keith Hartley,
Director -
Investment Group Lp Senator,
10% owner -
Invest Corp Zein Youssef El...,
-
Hans Mueller,
Director -
James B Wyngaarden,
Director -
Invest Corp Pillar Pharmace...,
-
Invest Corp Pillar Partners...,
-
Invest Corp Pillar Partners...,
-
Daniel B Soland,
CHIEF OPERATING OFFICER -
John Clayton Taylor,
Chief Executive Officer -
Ronald J Wooten,
Director -
Carl N Kraus,
Chief Medical Officer -
Daniel Salain,
Chief Operating Officer -
Co Investment Fund Xv, L.P....,